Skip to main content
. Author manuscript; available in PMC: 2022 Jul 19.
Published in final edited form as: Cancer Res. 2020 Aug 14;80(21):4754–4767. doi: 10.1158/0008-5472.CAN-20-0285

Figure 5. The tumor-infiltrating Chi3l3-positive cells are a subset of Arginase-1 and DAC affects TILs.

Figure 5.

(A) The total number of Arg1+ cells is not increased by DAC treatment. (B) Double IF reveals partial overlap of Chi3l3/4 with PD-L1, although the two antigens have different subcellular distributions (punctate pattern for PD-L1). Data are from treatment Paradigm I. (C) Sequential combination therapy with DAC followed by anti-PD-1 leads to an increase in CD8+ TILs, compared to treatment with DAC alone. The number of cases for cell counting reflects the number of histological blocks available.